Choline Alphoscerate in Prevention of Cognitive Deficiency Progressing in Relatives of Patients with Alzheimer’s Disease

The objective: of the study was to perform the comparative evaluation of three-year observation of cognitive dysfunction indices dynamics during conducting repeated courses of preventive treatment with choline alfoscerate (Cereton), which was assigned to first-degree relatives of patients with Alzheimer’s disease (AD). Materials and methods: first-degree relatives of patients with Alzheimer’s disease were included in the study. Changes in cognitive functioning indices were compared between the group, consisting of 30 relatives (9 subjects with mild cognitive impairment syndrome and 21 participants with signs of cognitive impairment), who had received three courses of 3-months therapy with choline alfoscerate (Cereton) at a daily dose of 1200 mg for three years, and the group, including 32 relatives, who had not received treatment with drugs. Methods. Clinical-psychological, psychometric, molecular-genetic, neurointrascopic, and statistical methods were used. Results: transition from mild cognitive impairment (MCI) syndrome was established in 28.7% of cases in therapeutic group. Significant reduction in cognitive dysfunction within the framework of MCI syndrome, as well as a decrease in cognitive dysfunction intensity were noticed in 66.7% of cases. Positive effect of treatment, assessed according to CGI (Clinical Global Impression scale) was established in 56.7% of relatives, included in the study. Statistically significant improvement of MMSE (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) indices, as well as indices of tests, differentially assessing various components of cognitive functioning, was achieved in therapeutic group, while in the group of relatives, who had not received drug treatment, significant worsening of cognitive functioning indices was revealed. Conclusion: the results of preventive course treatment with choline alfoscerate showed positive effect of the drug on the cognitive status of close relatives of patients with AD up to transition of the syndrome of mild cognitive impairment.

1. Prince M, Wimo AGM, Ali GC, Wu YT, Prina M. World Alzheimer Report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends. London: Alzheimer’s DiseaseInternational. 2015:1–23. https://www.alz.co.uk/research/world-report-2015.

2. Gavrilova SI, Kalyn YaB. Social and environmental factors and condition of mental health of the elderly population (clinico-epidemiological research). Vestnik RAMN. 2002;9:15–20. (In Russ.).

3. Chikina ES, Mednikov OI, Belousov YuB. Pharmacoeconomic aspects of treatment of dementia in the Russian Federation. Russkij medicinskij zhurnal. 2005;13(20):1354–1360. (In Russ.).

4. Jarvik LF, Brazer D. Children of Alzheimer parents: An Overview. J. Geriatr. Psychiatry Neurol. 2005;18:181–186. DOI.org/10.1177/0891988705281859.

5. Saunders AM, Strittmatter WJ, Schmechel D, St George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-Mac Lachlan DR, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD. Association of apolipoprotein E allele ɛ4 with late-onset familial and sporadic Alzheimer’s dis-ease. Neurology. 1993;43:1467–1472. DOI:10.1212/wnl.43.8.1467.

6. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions. Neuron.1993;11:575–580. DOI:10.1016/0896-6273(93)90070-8.

7. Roses AD. Apolipоprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer’s disease. Ann. Neurol. 1995;38:6–14. DOI:10.1002/ana.410380105.

8. Korovaytseva GI, Chipped TV, Seleznеva ND, Gavrilova SI, Golimbet VE, Voskresenskaya NI, Rogayev EI. Genetic association between alleles of a gene of E (APOE) apolipoprotein and various forms of Alzheimer’s disease. Genetics. 2001;37(4):529–533. (In Russ.). https://DOI.org/10.1023/A:1016610727938

9. Corbo RM, Scacchi R. Apolipiprotein E (APOE) allele distribution in the world. Is APOE*4 a “thrifly” allele? Ann. Hum. Genet. 1999;63:301–310. DOI:10.1046/j.1469-1809.1999.6340301.x.

10. Selezneva ND, Roshchina IF, Gavrilova SI, Fedorova YaB, Gantman MV, Korovaytseva GI, Kunizheva SS, Rogayev EI. Mental disturbances of a cognitive and not cognitive range at relatives of 1 degree of relationship of patients with Alzheimer’s disease. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2012;112(10):8–13. (In Russ.). https://doi.org/10.1177/0891988705281882.

11. Selezneva ND, Gavrilova SI, Roshchina IF, Korovaytseva GI. ApoE genotipe and mental disturbances of a cognitive and not cognitive range at relatives of the 1st degree of relationship of patients with Alzheimer’s disease. Psychiatry. 2013;1(57):13–23. (In Russ.).

12. Sager MA, Hermann B, La Rue A. Middle-aged children of persons with Alzheimer’s disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer’s Prevention. J. Geriatr. Psychiatry Neurol. 2005:18(4):245–249.

13. Selezneva N, Roshchina IA. comprehensive follow-up clinical and psychological study of cognitive features of mental activity in relatives of the first degree of relationship of patients with Alzheimer’s disease. Psychiatry. 2017;76(04):27–36. (In Russ.).

14. Amenta F, Franch F, Ricci A, Vega JA. Cholinegic neurotransmission in the hippocampus of ages rats: influence of alpha-glycerilphosphorylcholine treatment. Ann. NY Acad. Sci. 1993;695:311–313. DOI:10.1111/j.1749-6632.1993.tb23073.x.

15. Aleppo G, Nicoletti F, Sortino MA, Casabona G, Scapagnini U, Canonico PL. Chronic alpha-glycerilphosphorylcholine increases inisitol phosphate formation in brain slices and neuronal cultures. Pharmacol. Toxicol. 1994;74:5–100. DOI. org/10.1111/j.1600-0773.1994.tb01082.x.

16. Ban TA, Pansarasa RM, Borra S., Del Duchetto D, Fjetland OK. Choline alphoscerate in elderly patients with cognitive decline due to dementing illness. New Trends of Clinical Neuropharmacology. 1991;5:1–35. DOI:10.1016/s0047-6374(01)00312-8.

17. Selezneva ND, Roshchina IF, Gavrilova SI. Methods of neurometabolic therapy in prevention of cognitive deficiency at relatives of 1 degree of relationship of patients with Alzheimer’s disease. Sovremennaya terapiya v psihiatrii i nevrologii. 2018;3-4:8–18. (In Russ.).

18. Dubois Р, Albert M. Amnestic MCI or prodromal Alzheimer’s disease? Lancet Neurology. 2004;3:246–248. DOI:10.1016/S1474-4422(04)00710-0.

19. Gavrilova SI, Alesenko AV, Kolykhalov IV, Fedorova YaB, Seleznеva ND, Ponomareva EV, Guryanova SV, Gutner UA, Shupik MA. Clinical and biological effects of Cereton in the treatment of a syndrome of amnestic mild cognitive impairment. Psychiatry. 2017;1(73):5–15. (In Russ.) DOI 10.1007/s11055-018-0708-z.

20. Alesenko AV, Gavrilova SI, Gutner UA, Lebedeva AO, Shupik MA, Kolykhalov IV, Ponomareva EV, Seleznyova ND, Fedorova YaB. Detection of effective treatment of amnestic mild cognitive impairment with Cereton by testing of lipids markers Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2017;117(6):21–27. (In Russ.). DOI:10.17116/jnevro20171176121-27.

21. Kolykhalov IV, Gavrilova SI. The prolonged effects of Choline alphoscerate at patients with a syndrome of mild cognitive impairmentof amnestic type. Pacific medical J. 2019;(1):18–22. (In Russ.). DOI:10.17238/PmJ1609-1175.2019.1.18-22.